NO320028B1 - Substituerte 1-Okso- og 1,3-dioksoisoindoliner og deres anvendelse i farmasoytiske preparater for a redusere inflammatoriske cykotin nivaer - Google Patents

Info

Publication number

NO320028B1

NO320028B1 NO20013982A NO20013982A NO320028B1 NO 320028 B1 NO320028 B1 NO 320028B1 NO 20013982 A NO20013982 A NO 20013982A NO 20013982 A NO20013982 A NO 20013982A NO 320028 B1 NO320028 B1 NO 320028B1

Authority

NO

Norway

Prior art keywords

acid

dioxoisoindolin

oxoisoindolin

carbamoylbutanoic

nitro

Prior art date

1999-03-18

Links

• Espacenet
• Global Dossier
• Discuss

• 230000002757 inflammatory effect Effects 0.000 title claims abstract description 12
• XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 title claims abstract description 4
• 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
• 108090000695 Cytokines Proteins 0.000 claims abstract description 15
• 102000004127 Cytokines Human genes 0.000 claims abstract description 14
• 241000124008 Mammalia Species 0.000 claims abstract description 7
• 150000001875 compounds Chemical class 0.000 claims description 34
• 239000000203 mixture Substances 0.000 claims description 26
• 239000001257 hydrogen Substances 0.000 claims description 15
• 229910052739 hydrogen Inorganic materials 0.000 claims description 15
• XMKUEWQZKLDLQQ-UHFFFAOYSA-N 5-amino-2-(4-nitro-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical group C1=CC([N+]([O-])=O)=C2C(=O)N(C(CCC(=O)N)C(O)=O)C(=O)C2=C1 XMKUEWQZKLDLQQ-UHFFFAOYSA-N 0.000 claims description 12
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
• WHGCSJYLVKPHSS-UHFFFAOYSA-N 2-(4-nitro-1,3-dioxoisoindol-2-yl)pentanedioic acid Chemical group C1=CC([N+]([O-])=O)=C2C(=O)N(C(CCC(=O)O)C(O)=O)C(=O)C2=C1 WHGCSJYLVKPHSS-UHFFFAOYSA-N 0.000 claims description 7
• 125000000217 alkyl group Chemical group 0.000 claims description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
• 150000003839 salts Chemical class 0.000 claims description 7
• XSKMMEVRGHPMSJ-UHFFFAOYSA-N 5-amino-2-(4-amino-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical group C1=CC(N)=C2C(=O)N(C(CCC(=O)N)C(O)=O)C(=O)C2=C1 XSKMMEVRGHPMSJ-UHFFFAOYSA-N 0.000 claims description 6
• 125000004432 carbon atom Chemical group C* 0.000 claims description 6
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
• 150000002431 hydrogen Chemical class 0.000 claims description 5
• XYCTTXSUXYHEGZ-UHFFFAOYSA-N 4-amino-2-(4-amino-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical group C1=CC(N)=C2C(=O)N(C(CC(=O)N)C(O)=O)C(=O)C2=C1 XYCTTXSUXYHEGZ-UHFFFAOYSA-N 0.000 claims description 4
• 229910052799 carbon Inorganic materials 0.000 claims description 4
• CASOMQVHZDICDH-UHFFFAOYSA-N 5-amino-2-(4-methyl-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical group CC1=CC=CC2=C1C(=O)N(C(CCC(N)=O)C(O)=O)C2=O CASOMQVHZDICDH-UHFFFAOYSA-N 0.000 claims description 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
• GMZFKVRMIVHGOK-UHFFFAOYSA-N 2-(4-methyl-1,3-dioxoisoindol-2-yl)pentanedioic acid Chemical group CC1=CC=CC2=C1C(=O)N(C(CCC(O)=O)C(O)=O)C2=O GMZFKVRMIVHGOK-UHFFFAOYSA-N 0.000 claims description 2
• HNVVLGMTFHERFZ-UHFFFAOYSA-N 4-amino-3-methyl-2-(4-nitro-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical group C1=CC([N+]([O-])=O)=C2C(=O)N(C(C(C)C(N)=O)C(O)=O)C(=O)C2=C1 HNVVLGMTFHERFZ-UHFFFAOYSA-N 0.000 claims description 2
• 125000002252 acyl group Chemical group 0.000 claims description 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
• 125000001475 halogen functional group Chemical group 0.000 claims 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 51
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 51
• JVYMXRZSOURPSE-UHFFFAOYSA-N 5-amino-4-(4-amino-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical group C1=CC(N)=C2C(=O)N(C(CCC(O)=O)C(=O)N)C(=O)C2=C1 JVYMXRZSOURPSE-UHFFFAOYSA-N 0.000 abstract description 2
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
• 230000033115 angiogenesis Effects 0.000 description 24
• 206010028980 Neoplasm Diseases 0.000 description 23
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
• 238000011282 treatment Methods 0.000 description 23
• 201000010099 disease Diseases 0.000 description 22
• 210000004027 cell Anatomy 0.000 description 21
• 241000725303 Human immunodeficiency virus Species 0.000 description 17
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
• 239000002253 acid Substances 0.000 description 14
• HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 13
• RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 13
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 13
• JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 13
• 201000011510 cancer Diseases 0.000 description 13
• 239000001384 succinic acid Substances 0.000 description 13
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
• 210000001744 T-lymphocyte Anatomy 0.000 description 12
• 239000003814 drug Substances 0.000 description 12
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
• 108700012920 TNF Proteins 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 230000000694 effects Effects 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• 208000030507 AIDS Diseases 0.000 description 8
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• 241000700605 Viruses Species 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 238000000034 method Methods 0.000 description 8
• 208000031886 HIV Infections Diseases 0.000 description 7
• 230000004913 activation Effects 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 230000010076 replication Effects 0.000 description 7
• -1 tetrahydrocortisol Chemical class 0.000 description 7
• 230000004614 tumor growth Effects 0.000 description 7
• 206010061218 Inflammation Diseases 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 239000003112 inhibitor Substances 0.000 description 6
• 210000002540 macrophage Anatomy 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• ROFZMKDROVBLNY-UHFFFAOYSA-N 4-nitro-2-benzofuran-1,3-dione Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(=O)OC2=O ROFZMKDROVBLNY-UHFFFAOYSA-N 0.000 description 5
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
• 239000002246 antineoplastic agent Substances 0.000 description 5
• 238000004587 chromatography analysis Methods 0.000 description 5
• 210000002889 endothelial cell Anatomy 0.000 description 5
• 230000014509 gene expression Effects 0.000 description 5
• 208000024908 graft versus host disease Diseases 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 238000010992 reflux Methods 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
• 206010029113 Neovascularisation Diseases 0.000 description 4
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
• 206010040070 Septic Shock Diseases 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 239000004037 angiogenesis inhibitor Substances 0.000 description 4
• 206010003246 arthritis Diseases 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 229940127089 cytotoxic agent Drugs 0.000 description 4
• 229960002989 glutamic acid Drugs 0.000 description 4
• GTFMAONWNTUZEW-UHFFFAOYSA-N glutaramic acid Chemical compound NC(=O)CCCC(O)=O GTFMAONWNTUZEW-UHFFFAOYSA-N 0.000 description 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 208000032839 leukemia Diseases 0.000 description 4
• 201000004792 malaria Diseases 0.000 description 4
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 239000011541 reaction mixture Substances 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 230000035939 shock Effects 0.000 description 4
• 239000002002 slurry Substances 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 150000003431 steroids Chemical class 0.000 description 4
• 208000011580 syndromic disease Diseases 0.000 description 4
• 230000006433 tumor necrosis factor production Effects 0.000 description 4
• 230000029812 viral genome replication Effects 0.000 description 4
• FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 3
• WSZDWVVHNBZAEC-UHFFFAOYSA-N 4-amino-2-(4-nitro-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC([N+]([O-])=O)=C2C(=O)N(C(CC(=O)N)C(O)=O)C(=O)C2=C1 WSZDWVVHNBZAEC-UHFFFAOYSA-N 0.000 description 3
• 206010006895 Cachexia Diseases 0.000 description 3
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
• 230000006820 DNA synthesis Effects 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 208000009329 Graft vs Host Disease Diseases 0.000 description 3
• 208000037357 HIV infectious disease Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 208000001388 Opportunistic Infections Diseases 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 230000018199 S phase Effects 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 239000012190 activator Substances 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• 230000001093 anti-cancer Effects 0.000 description 3
• 210000000481 breast Anatomy 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 239000003974 emollient agent Substances 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 229960002949 fluorouracil Drugs 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 239000004220 glutamic acid Substances 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• 102000057041 human TNF Human genes 0.000 description 3
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000008018 melting Effects 0.000 description 3
• 229960004023 minocycline Drugs 0.000 description 3
• 210000001616 monocyte Anatomy 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 230000001613 neoplastic effect Effects 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 230000000451 tissue damage Effects 0.000 description 3
• 231100000827 tissue damage Toxicity 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• KQOKYLBWODYVIR-UHFFFAOYSA-N 2-(4-amino-1,3-dioxoisoindol-2-yl)pentanedioic acid Chemical compound NC1=CC=CC2=C1C(=O)N(C(CCC(O)=O)C(O)=O)C2=O KQOKYLBWODYVIR-UHFFFAOYSA-N 0.000 description 2
• JGYBMOPXWMVNLQ-UHFFFAOYSA-N 4-amino-2-(1,3-dioxo-4-propan-2-ylisoindol-2-yl)-4-oxobutanoic acid Chemical compound CC(C)C1=CC=CC2=C1C(=O)N(C(CC(N)=O)C(O)=O)C2=O JGYBMOPXWMVNLQ-UHFFFAOYSA-N 0.000 description 2
• IFDZOMVNICEWHH-UHFFFAOYSA-N 5-amino-4-(4-nitro-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical compound C1=CC([N+]([O-])=O)=C2C(=O)N(C(CCC(O)=O)C(=O)N)C(=O)C2=C1 IFDZOMVNICEWHH-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 2
• 208000006386 Bone Resorption Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 206010014824 Endotoxic shock Diseases 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• AEFLONBTGZFSGQ-VKHMYHEASA-N L-isoglutamine Chemical compound NC(=O)[C@@H](N)CCC(O)=O AEFLONBTGZFSGQ-VKHMYHEASA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 206010024229 Leprosy Diseases 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
• 102000007327 Protamines Human genes 0.000 description 2
• 108010007568 Protamines Proteins 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• 230000002491 angiogenic effect Effects 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 101150044616 araC gene Proteins 0.000 description 2
• 230000002917 arthritic effect Effects 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 238000009739 binding Methods 0.000 description 2
• 230000027455 binding Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 230000024279 bone resorption Effects 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 210000004087 cornea Anatomy 0.000 description 2
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
• 229960005304 fludarabine phosphate Drugs 0.000 description 2
• NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 2
• 108091006104 gene-regulatory proteins Proteins 0.000 description 2
• 102000034356 gene-regulatory proteins Human genes 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000004968 inflammatory condition Effects 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000007302 negative regulation of cytokine production Effects 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 230000002947 procoagulating effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 229940048914 protamine Drugs 0.000 description 2
• 108090000623 proteins and genes Proteins 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 230000005588 protonation Effects 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 210000003556 vascular endothelial cell Anatomy 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
• DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
• AODPIQQILQLWGS-UHFFFAOYSA-N (3alpa,5beta,11beta,17alphaOH)-form-3,11,17,21-Tetrahydroxypregnan-20-one, Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 AODPIQQILQLWGS-UHFFFAOYSA-N 0.000 description 1
• GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
• KYTQRLKXTUZCIH-UHFFFAOYSA-N 2-(1,3-dioxo-4-propan-2-ylisoindol-2-yl)butanedioic acid Chemical compound CC(C)C1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(O)=O)C2=O KYTQRLKXTUZCIH-UHFFFAOYSA-N 0.000 description 1
• XVZAVIHBETVGSQ-UHFFFAOYSA-N 2-(1,3-dioxo-4-propylisoindol-2-yl)butanedioic acid Chemical compound CCCC1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(O)=O)C2=O XVZAVIHBETVGSQ-UHFFFAOYSA-N 0.000 description 1
• PLVWEGSABPGFJW-UHFFFAOYSA-N 2-(1-amino-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound C1=CC=C2C(N)N(C(CC(O)=O)C(O)=O)C(=O)C2=C1 PLVWEGSABPGFJW-UHFFFAOYSA-N 0.000 description 1
• YYJRIODZWRNGBD-UHFFFAOYSA-N 2-(1-amino-3-oxo-1h-isoindol-2-yl)pentanedioic acid Chemical compound C1=CC=C2C(N)N(C(CCC(O)=O)C(O)=O)C(=O)C2=C1 YYJRIODZWRNGBD-UHFFFAOYSA-N 0.000 description 1
• RHNSEIYTDIYOSC-UHFFFAOYSA-N 2-(1-butyl-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound C1=CC=C2C(CCCC)N(C(CC(O)=O)C(O)=O)C(=O)C2=C1 RHNSEIYTDIYOSC-UHFFFAOYSA-N 0.000 description 1
• VPXSIRYZDVCLNB-UHFFFAOYSA-N 2-(1-butyl-3-oxo-1h-isoindol-2-yl)pentanedioic acid Chemical compound C1=CC=C2C(CCCC)N(C(CCC(O)=O)C(O)=O)C(=O)C2=C1 VPXSIRYZDVCLNB-UHFFFAOYSA-N 0.000 description 1
• XTELVOMYAQKLHC-UHFFFAOYSA-N 2-(1-ethyl-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound C1=CC=C2C(CC)N(C(CC(O)=O)C(O)=O)C(=O)C2=C1 XTELVOMYAQKLHC-UHFFFAOYSA-N 0.000 description 1
• CBURZBDLOCAYSJ-UHFFFAOYSA-N 2-(1-ethyl-3-oxo-1h-isoindol-2-yl)pentanedioic acid Chemical compound C1=CC=C2C(CC)N(C(CCC(O)=O)C(O)=O)C(=O)C2=C1 CBURZBDLOCAYSJ-UHFFFAOYSA-N 0.000 description 1
• TVUKAZVBQDDPEV-UHFFFAOYSA-N 2-(1-methyl-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound C1=CC=C2C(C)N(C(CC(O)=O)C(O)=O)C(=O)C2=C1 TVUKAZVBQDDPEV-UHFFFAOYSA-N 0.000 description 1
• HARWOAUWXHDTRW-UHFFFAOYSA-N 2-(1-methyl-3-oxo-1h-isoindol-2-yl)pentanedioic acid Chemical compound C1=CC=C2C(C)N(C(CCC(O)=O)C(O)=O)C(=O)C2=C1 HARWOAUWXHDTRW-UHFFFAOYSA-N 0.000 description 1
• FLBSTNAYHCCMBD-UHFFFAOYSA-N 2-(1-nitro-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound C1=CC=C2C(=O)N(C(CC(=O)O)C(O)=O)C([N+]([O-])=O)C2=C1 FLBSTNAYHCCMBD-UHFFFAOYSA-N 0.000 description 1
• SDKFMKDRYPLOKB-UHFFFAOYSA-N 2-(1-nitro-3-oxo-1h-isoindol-2-yl)pentanedioic acid Chemical compound C1=CC=C2C(=O)N(C(CCC(=O)O)C(O)=O)C([N+]([O-])=O)C2=C1 SDKFMKDRYPLOKB-UHFFFAOYSA-N 0.000 description 1
• PTWHGLJVRQLOAF-UHFFFAOYSA-N 2-(3-oxo-1-propan-2-yl-1h-isoindol-2-yl)butanedioic acid Chemical compound C1=CC=C2C(C(C)C)N(C(CC(O)=O)C(O)=O)C(=O)C2=C1 PTWHGLJVRQLOAF-UHFFFAOYSA-N 0.000 description 1
• YRLKPJRSSATUAL-UHFFFAOYSA-N 2-(3-oxo-1-propan-2-yl-1h-isoindol-2-yl)pentanedioic acid Chemical compound C1=CC=C2C(C(C)C)N(C(CCC(O)=O)C(O)=O)C(=O)C2=C1 YRLKPJRSSATUAL-UHFFFAOYSA-N 0.000 description 1
• WERMFFKHAYXENH-UHFFFAOYSA-N 2-(3-oxo-1-propyl-1h-isoindol-2-yl)butanedioic acid Chemical compound C1=CC=C2C(CCC)N(C(CC(O)=O)C(O)=O)C(=O)C2=C1 WERMFFKHAYXENH-UHFFFAOYSA-N 0.000 description 1
• BKMMKUKELLCLIC-UHFFFAOYSA-N 2-(3-oxo-1-propyl-1h-isoindol-2-yl)pentanedioic acid Chemical compound C1=CC=C2C(CCC)N(C(CCC(O)=O)C(O)=O)C(=O)C2=C1 BKMMKUKELLCLIC-UHFFFAOYSA-N 0.000 description 1
• JGGAJJQYFLPBTA-UHFFFAOYSA-N 2-(3-oxo-7-propan-2-yl-1h-isoindol-2-yl)butanedioic acid Chemical compound CC(C)C1=CC=CC2=C1CN(C(CC(O)=O)C(O)=O)C2=O JGGAJJQYFLPBTA-UHFFFAOYSA-N 0.000 description 1
• WMAKZCILZQLGHS-UHFFFAOYSA-N 2-(3-oxo-7-propan-2-yl-1h-isoindol-2-yl)pentanedioic acid Chemical compound CC(C)C1=CC=CC2=C1CN(C(CCC(O)=O)C(O)=O)C2=O WMAKZCILZQLGHS-UHFFFAOYSA-N 0.000 description 1
• GYLXJKMUPUSVSZ-UHFFFAOYSA-N 2-(3-oxo-7-propyl-1h-isoindol-2-yl)pentanedioic acid Chemical compound CCCC1=CC=CC2=C1CN(C(CCC(O)=O)C(O)=O)C2=O GYLXJKMUPUSVSZ-UHFFFAOYSA-N 0.000 description 1
• NMDGAMYAKJIZPQ-UHFFFAOYSA-N 2-(4-amino-1,3-dioxoisoindol-2-yl)butanedioic acid Chemical compound NC1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(O)=O)C2=O NMDGAMYAKJIZPQ-UHFFFAOYSA-N 0.000 description 1
• BGQJBSGIZKROSB-UHFFFAOYSA-N 2-(4-butyl-1,3-dioxoisoindol-2-yl)butanedioic acid Chemical compound CCCCC1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(O)=O)C2=O BGQJBSGIZKROSB-UHFFFAOYSA-N 0.000 description 1
• LJFAWJBCIOOZIZ-UHFFFAOYSA-N 2-(4-ethyl-1,3-dioxoisoindol-2-yl)butanedioic acid Chemical compound CCC1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(O)=O)C2=O LJFAWJBCIOOZIZ-UHFFFAOYSA-N 0.000 description 1
• JPNGOBFHKWUBEL-UHFFFAOYSA-N 2-(4-methyl-1,3-dioxoisoindol-2-yl)butanedioic acid Chemical compound CC1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(O)=O)C2=O JPNGOBFHKWUBEL-UHFFFAOYSA-N 0.000 description 1
• ORDUWGYROYYTAZ-UHFFFAOYSA-N 2-(4-nitro-1,3-dioxoisoindol-2-yl)butanedioic acid Chemical compound C1=CC([N+]([O-])=O)=C2C(=O)N(C(CC(=O)O)C(O)=O)C(=O)C2=C1 ORDUWGYROYYTAZ-UHFFFAOYSA-N 0.000 description 1
• SLIHQYUOOBCMQU-UHFFFAOYSA-N 2-(7-amino-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound NC1=CC=CC2=C1CN(C(CC(O)=O)C(O)=O)C2=O SLIHQYUOOBCMQU-UHFFFAOYSA-N 0.000 description 1
• DVFZIZCDDQITQV-UHFFFAOYSA-N 2-(7-amino-3-oxo-1h-isoindol-2-yl)pentanedioic acid Chemical compound NC1=CC=CC2=C1CN(C(CCC(O)=O)C(O)=O)C2=O DVFZIZCDDQITQV-UHFFFAOYSA-N 0.000 description 1
• XXKIWUVNTNBKAG-UHFFFAOYSA-N 2-(7-butyl-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound CCCCC1=CC=CC2=C1CN(C(CC(O)=O)C(O)=O)C2=O XXKIWUVNTNBKAG-UHFFFAOYSA-N 0.000 description 1
• KCMJXUDGFZVBLE-UHFFFAOYSA-N 2-(7-ethyl-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound CCC1=CC=CC2=C1CN(C(CC(O)=O)C(O)=O)C2=O KCMJXUDGFZVBLE-UHFFFAOYSA-N 0.000 description 1
• AFVIQGZDTJYYAY-UHFFFAOYSA-N 2-(7-ethyl-3-oxo-1h-isoindol-2-yl)pentanedioic acid Chemical compound CCC1=CC=CC2=C1CN(C(CCC(O)=O)C(O)=O)C2=O AFVIQGZDTJYYAY-UHFFFAOYSA-N 0.000 description 1
• STVHSDXZBYRNSN-UHFFFAOYSA-N 2-(7-methyl-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound CC1=CC=CC2=C1CN(C(CC(O)=O)C(O)=O)C2=O STVHSDXZBYRNSN-UHFFFAOYSA-N 0.000 description 1
• CZSOXNBJESOPRV-UHFFFAOYSA-N 2-(7-methyl-3-oxo-1h-isoindol-2-yl)pentanedioic acid Chemical compound CC1=CC=CC2=C1CN(C(CCC(O)=O)C(O)=O)C2=O CZSOXNBJESOPRV-UHFFFAOYSA-N 0.000 description 1
• QGAAJLZWQIATLL-UHFFFAOYSA-N 2-(7-nitro-3-oxo-1h-isoindol-2-yl)butanedioic acid Chemical compound O=C1N(C(CC(=O)O)C(O)=O)CC2=C1C=CC=C2[N+]([O-])=O QGAAJLZWQIATLL-UHFFFAOYSA-N 0.000 description 1
• RZPMMKDWVZJPMQ-UHFFFAOYSA-N 2-(7-nitro-3-oxo-1h-isoindol-2-yl)pentanedioic acid Chemical compound O=C1N(C(CCC(=O)O)C(O)=O)CC2=C1C=CC=C2[N+]([O-])=O RZPMMKDWVZJPMQ-UHFFFAOYSA-N 0.000 description 1
• KLOWCYYNFIUKMV-UHFFFAOYSA-N 4-amino-2-(1,3-dioxo-4-propylisoindol-2-yl)-4-oxobutanoic acid Chemical compound CCCC1=CC=CC2=C1C(=O)N(C(CC(N)=O)C(O)=O)C2=O KLOWCYYNFIUKMV-UHFFFAOYSA-N 0.000 description 1
• CLPYCGWFQRTVJR-UHFFFAOYSA-N 4-amino-2-(1-butyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(CCCC)N(C(CC(N)=O)C(O)=O)C(=O)C2=C1 CLPYCGWFQRTVJR-UHFFFAOYSA-N 0.000 description 1
• KFPOJOUMQLYVGQ-UHFFFAOYSA-N 4-amino-2-(1-ethyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(CC)N(C(CC(N)=O)C(O)=O)C(=O)C2=C1 KFPOJOUMQLYVGQ-UHFFFAOYSA-N 0.000 description 1
• TXWFFPPYDGKGNS-UHFFFAOYSA-N 4-amino-2-(1-methyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(C)N(C(CC(N)=O)C(O)=O)C(=O)C2=C1 TXWFFPPYDGKGNS-UHFFFAOYSA-N 0.000 description 1
• FKNCRAPKSWWHJH-UHFFFAOYSA-N 4-amino-2-(1-nitro-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(=O)N(C(CC(=O)N)C(O)=O)C([N+]([O-])=O)C2=C1 FKNCRAPKSWWHJH-UHFFFAOYSA-N 0.000 description 1
• YJVAEMRBOALCAK-UHFFFAOYSA-N 4-amino-2-(4-butyl-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical compound CCCCC1=CC=CC2=C1C(=O)N(C(CC(N)=O)C(O)=O)C2=O YJVAEMRBOALCAK-UHFFFAOYSA-N 0.000 description 1
• ZJIUIECPCFMEGR-UHFFFAOYSA-N 4-amino-2-(4-ethyl-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical compound CCC1=CC=CC2=C1C(=O)N(C(CC(N)=O)C(O)=O)C2=O ZJIUIECPCFMEGR-UHFFFAOYSA-N 0.000 description 1
• GZGWYHVMSPVTPV-UHFFFAOYSA-N 4-amino-2-(4-methyl-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical compound CC1=CC=CC2=C1C(=O)N(C(CC(N)=O)C(O)=O)C2=O GZGWYHVMSPVTPV-UHFFFAOYSA-N 0.000 description 1
• DUBQMVCLIXQMAZ-UHFFFAOYSA-N 4-amino-2-(7-butyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound CCCCC1=CC=CC2=C1CN(C(CC(N)=O)C(O)=O)C2=O DUBQMVCLIXQMAZ-UHFFFAOYSA-N 0.000 description 1
• SESBOAOAHMISPK-UHFFFAOYSA-N 4-amino-2-(7-ethyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound CCC1=CC=CC2=C1CN(C(CC(N)=O)C(O)=O)C2=O SESBOAOAHMISPK-UHFFFAOYSA-N 0.000 description 1
• SRWBJIUCNSXICI-UHFFFAOYSA-N 4-amino-2-(7-methyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound CC1=CC=CC2=C1CN(C(CC(N)=O)C(O)=O)C2=O SRWBJIUCNSXICI-UHFFFAOYSA-N 0.000 description 1
• JYECEBQEZVTVLL-UHFFFAOYSA-N 4-amino-3-(1,3-dioxo-4-propylisoindol-2-yl)-4-oxobutanoic acid Chemical compound CCCC1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(N)=O)C2=O JYECEBQEZVTVLL-UHFFFAOYSA-N 0.000 description 1
• DWUXFEUMEBTEQS-UHFFFAOYSA-N 4-amino-3-(1-butyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(CCCC)N(C(CC(O)=O)C(N)=O)C(=O)C2=C1 DWUXFEUMEBTEQS-UHFFFAOYSA-N 0.000 description 1
• GHBGLFOQDFLIIH-UHFFFAOYSA-N 4-amino-3-(1-ethyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(CC)N(C(CC(O)=O)C(N)=O)C(=O)C2=C1 GHBGLFOQDFLIIH-UHFFFAOYSA-N 0.000 description 1
• PSJQSQXVGHSRDH-UHFFFAOYSA-N 4-amino-3-(1-methyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(C)N(C(CC(O)=O)C(N)=O)C(=O)C2=C1 PSJQSQXVGHSRDH-UHFFFAOYSA-N 0.000 description 1
• KAVNWXNGATWEDC-UHFFFAOYSA-N 4-amino-3-(1-nitro-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(=O)N(C(CC(O)=O)C(=O)N)C([N+]([O-])=O)C2=C1 KAVNWXNGATWEDC-UHFFFAOYSA-N 0.000 description 1
• YNHQXGZFCAVLPS-UHFFFAOYSA-N 4-amino-3-(4-butyl-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical compound CCCCC1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(N)=O)C2=O YNHQXGZFCAVLPS-UHFFFAOYSA-N 0.000 description 1
• ATQTVFLGHXKDJN-UHFFFAOYSA-N 4-amino-3-(4-ethyl-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical compound CCC1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(N)=O)C2=O ATQTVFLGHXKDJN-UHFFFAOYSA-N 0.000 description 1
• PPLZIAGPLUZTHN-UHFFFAOYSA-N 4-amino-3-(4-methyl-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical compound CC1=CC=CC2=C1C(=O)N(C(CC(O)=O)C(N)=O)C2=O PPLZIAGPLUZTHN-UHFFFAOYSA-N 0.000 description 1
• ZYANIBLPALGOHP-UHFFFAOYSA-N 4-amino-3-(4-nitro-1,3-dioxoisoindol-2-yl)-4-oxobutanoic acid Chemical compound C1=CC([N+]([O-])=O)=C2C(=O)N(C(CC(O)=O)C(=O)N)C(=O)C2=C1 ZYANIBLPALGOHP-UHFFFAOYSA-N 0.000 description 1
• QEHUAODMRQTLGW-UHFFFAOYSA-N 4-amino-3-(7-ethyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound CCC1=CC=CC2=C1CN(C(CC(O)=O)C(N)=O)C2=O QEHUAODMRQTLGW-UHFFFAOYSA-N 0.000 description 1
• IPKMFRMLEYPICM-UHFFFAOYSA-N 4-amino-3-(7-methyl-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound CC1=CC=CC2=C1CN(C(CC(O)=O)C(N)=O)C2=O IPKMFRMLEYPICM-UHFFFAOYSA-N 0.000 description 1
• PJDGSDCRBKAJDH-UHFFFAOYSA-N 4-amino-3-(7-nitro-3-oxo-1h-isoindol-2-yl)-4-oxobutanoic acid Chemical compound O=C1N(C(CC(O)=O)C(=O)N)CC2=C1C=CC=C2[N+]([O-])=O PJDGSDCRBKAJDH-UHFFFAOYSA-N 0.000 description 1
• AVVBKGKSWJMDFR-UHFFFAOYSA-N 4-amino-4-oxo-2-(3-oxo-1-propan-2-yl-1h-isoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C(C(C)C)N(C(CC(N)=O)C(O)=O)C(=O)C2=C1 AVVBKGKSWJMDFR-UHFFFAOYSA-N 0.000 description 1
• VKQPKDFETQWEBZ-UHFFFAOYSA-N 4-amino-4-oxo-2-(3-oxo-1-propyl-1h-isoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C(CCC)N(C(CC(N)=O)C(O)=O)C(=O)C2=C1 VKQPKDFETQWEBZ-UHFFFAOYSA-N 0.000 description 1
• ZDJPXBIRWFWFII-UHFFFAOYSA-N 4-amino-4-oxo-2-(3-oxo-7-propan-2-yl-1h-isoindol-2-yl)butanoic acid Chemical compound CC(C)C1=CC=CC2=C1CN(C(CC(N)=O)C(O)=O)C2=O ZDJPXBIRWFWFII-UHFFFAOYSA-N 0.000 description 1
• RLUBPUMEMPTGCU-UHFFFAOYSA-N 4-amino-4-oxo-2-(3-oxo-7-propyl-1h-isoindol-2-yl)butanoic acid Chemical compound CCCC1=CC=CC2=C1CN(C(CC(N)=O)C(O)=O)C2=O RLUBPUMEMPTGCU-UHFFFAOYSA-N 0.000 description 1
• FKBPRIMPELADIL-UHFFFAOYSA-N 4-amino-4-oxo-3-(3-oxo-1-propan-2-yl-1h-isoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C(C(C)C)N(C(CC(O)=O)C(N)=O)C(=O)C2=C1 FKBPRIMPELADIL-UHFFFAOYSA-N 0.000 description 1
• BOUIWRNUTIHPBC-UHFFFAOYSA-N 4-amino-4-oxo-3-(3-oxo-1-propyl-1h-isoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C(CCC)N(C(CC(O)=O)C(N)=O)C(=O)C2=C1 BOUIWRNUTIHPBC-UHFFFAOYSA-N 0.000 description 1
• GNKCQSLAVSNNGA-UHFFFAOYSA-N 4-amino-4-oxo-3-(3-oxo-7-propan-2-yl-1h-isoindol-2-yl)butanoic acid Chemical compound CC(C)C1=CC=CC2=C1CN(C(CC(O)=O)C(N)=O)C2=O GNKCQSLAVSNNGA-UHFFFAOYSA-N 0.000 description 1
• NRBCPQSOJXUNCS-UHFFFAOYSA-N 4-amino-4-oxo-3-(3-oxo-7-propyl-1h-isoindol-2-yl)butanoic acid Chemical compound CCCC1=CC=CC2=C1CN(C(CC(O)=O)C(N)=O)C2=O NRBCPQSOJXUNCS-UHFFFAOYSA-N 0.000 description 1
• TWWAWPHAOPTQEU-UHFFFAOYSA-N 4-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=CC2=C1C(=O)OC2=O TWWAWPHAOPTQEU-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• HPQVKINWMSDUDM-UHFFFAOYSA-N 5-amino-2-(1,3-dioxo-4-propan-2-ylisoindol-2-yl)-5-oxopentanoic acid Chemical compound CC(C)C1=CC=CC2=C1C(=O)N(C(CCC(N)=O)C(O)=O)C2=O HPQVKINWMSDUDM-UHFFFAOYSA-N 0.000 description 1
• AUDVOVQPBNPQOE-UHFFFAOYSA-N 5-amino-2-(1,3-dioxo-4-propylisoindol-2-yl)-5-oxopentanoic acid Chemical compound CCCC1=CC=CC2=C1C(=O)N(C(CCC(N)=O)C(O)=O)C2=O AUDVOVQPBNPQOE-UHFFFAOYSA-N 0.000 description 1
• ZSSVUSCNBDLWLB-UHFFFAOYSA-N 5-amino-2-(1-amino-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound C1=CC=C2C(N)N(C(CCC(N)=O)C(O)=O)C(=O)C2=C1 ZSSVUSCNBDLWLB-UHFFFAOYSA-N 0.000 description 1
• VRJZPMOMPXTIRA-UHFFFAOYSA-N 5-amino-2-(1-butyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound C1=CC=C2C(CCCC)N(C(CCC(N)=O)C(O)=O)C(=O)C2=C1 VRJZPMOMPXTIRA-UHFFFAOYSA-N 0.000 description 1
• CHBVSLSSHQFTAS-UHFFFAOYSA-N 5-amino-2-(1-ethyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound C1=CC=C2C(CC)N(C(CCC(N)=O)C(O)=O)C(=O)C2=C1 CHBVSLSSHQFTAS-UHFFFAOYSA-N 0.000 description 1
• CFTJNUDKQAMSHV-UHFFFAOYSA-N 5-amino-2-(1-methyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound C1=CC=C2C(C)N(C(CCC(N)=O)C(O)=O)C(=O)C2=C1 CFTJNUDKQAMSHV-UHFFFAOYSA-N 0.000 description 1
• KRBBAFOXBAZRCY-UHFFFAOYSA-N 5-amino-2-(4-butyl-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical compound CCCCC1=CC=CC2=C1C(=O)N(C(CCC(N)=O)C(O)=O)C2=O KRBBAFOXBAZRCY-UHFFFAOYSA-N 0.000 description 1
• XSMMHSJELJPFSC-UHFFFAOYSA-N 5-amino-2-(4-ethyl-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical compound CCC1=CC=CC2=C1C(=O)N(C(CCC(N)=O)C(O)=O)C2=O XSMMHSJELJPFSC-UHFFFAOYSA-N 0.000 description 1
• KSCACLRGQJXDAB-UHFFFAOYSA-N 5-amino-2-(7-amino-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound O=C1N(C(CCC(=O)N)C(O)=O)CC2=C1C=CC=C2N KSCACLRGQJXDAB-UHFFFAOYSA-N 0.000 description 1
• IVZOIKCYHIILEC-UHFFFAOYSA-N 5-amino-2-(7-butyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound CCCCC1=CC=CC2=C1CN(C(CCC(N)=O)C(O)=O)C2=O IVZOIKCYHIILEC-UHFFFAOYSA-N 0.000 description 1
• QYENXFUDUQFEDV-UHFFFAOYSA-N 5-amino-2-(7-ethyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound CCC1=CC=CC2=C1CN(C(CCC(N)=O)C(O)=O)C2=O QYENXFUDUQFEDV-UHFFFAOYSA-N 0.000 description 1
• ASOZXVYBNIAJDS-UHFFFAOYSA-N 5-amino-2-(7-methyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound CC1=CC=CC2=C1CN(C(CCC(N)=O)C(O)=O)C2=O ASOZXVYBNIAJDS-UHFFFAOYSA-N 0.000 description 1
• JWXSMBGQHOFVJT-UHFFFAOYSA-N 5-amino-2-(7-nitro-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound O=C1N(C(CCC(=O)N)C(O)=O)CC2=C1C=CC=C2[N+]([O-])=O JWXSMBGQHOFVJT-UHFFFAOYSA-N 0.000 description 1
• VBYKESMNUUOSBJ-UHFFFAOYSA-N 5-amino-4-(1,3-dioxo-4-propan-2-ylisoindol-2-yl)-5-oxopentanoic acid Chemical compound CC(C)C1=CC=CC2=C1C(=O)N(C(CCC(O)=O)C(N)=O)C2=O VBYKESMNUUOSBJ-UHFFFAOYSA-N 0.000 description 1
• LKTDYXHMLHJSKE-UHFFFAOYSA-N 5-amino-4-(1,3-dioxo-4-propylisoindol-2-yl)-5-oxopentanoic acid Chemical compound CCCC1=CC=CC2=C1C(=O)N(C(CCC(O)=O)C(N)=O)C2=O LKTDYXHMLHJSKE-UHFFFAOYSA-N 0.000 description 1
• LEZCUUVOJNICQD-UHFFFAOYSA-N 5-amino-4-(1-amino-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound C1=CC=C2C(N)N(C(CCC(O)=O)C(N)=O)C(=O)C2=C1 LEZCUUVOJNICQD-UHFFFAOYSA-N 0.000 description 1
• JMSJVCDJPPDFKR-UHFFFAOYSA-N 5-amino-4-(1-ethyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound C1=CC=C2C(CC)N(C(CCC(O)=O)C(N)=O)C(=O)C2=C1 JMSJVCDJPPDFKR-UHFFFAOYSA-N 0.000 description 1
• IPKDRVRPKWDPCI-UHFFFAOYSA-N 5-amino-4-(1-methyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound C1=CC=C2C(C)N(C(CCC(O)=O)C(N)=O)C(=O)C2=C1 IPKDRVRPKWDPCI-UHFFFAOYSA-N 0.000 description 1
• CXIZBIBLPVPXMG-UHFFFAOYSA-N 5-amino-4-(4-butyl-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical compound CCCCC1=CC=CC2=C1C(=O)N(C(CCC(O)=O)C(N)=O)C2=O CXIZBIBLPVPXMG-UHFFFAOYSA-N 0.000 description 1
• YHBNBIDHJJHGMD-UHFFFAOYSA-N 5-amino-4-(4-ethyl-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical compound CCC1=CC=CC2=C1C(=O)N(C(CCC(O)=O)C(N)=O)C2=O YHBNBIDHJJHGMD-UHFFFAOYSA-N 0.000 description 1
• ZIZZHVNIDWVLGN-UHFFFAOYSA-N 5-amino-4-(4-methyl-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical compound CC1=CC=CC2=C1C(=O)N(C(CCC(O)=O)C(N)=O)C2=O ZIZZHVNIDWVLGN-UHFFFAOYSA-N 0.000 description 1
• USYWQLIFELNXTA-UHFFFAOYSA-N 5-amino-4-(7-amino-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound O=C1N(C(CCC(O)=O)C(=O)N)CC2=C1C=CC=C2N USYWQLIFELNXTA-UHFFFAOYSA-N 0.000 description 1
• JVZJEODDLZUSCJ-UHFFFAOYSA-N 5-amino-4-(7-butyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound CCCCC1=CC=CC2=C1CN(C(CCC(O)=O)C(N)=O)C2=O JVZJEODDLZUSCJ-UHFFFAOYSA-N 0.000 description 1
• YFKYZCYBNWIAGP-UHFFFAOYSA-N 5-amino-4-(7-ethyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound CCC1=CC=CC2=C1CN(C(CCC(O)=O)C(N)=O)C2=O YFKYZCYBNWIAGP-UHFFFAOYSA-N 0.000 description 1
• RXNLJUZQYUZNDX-UHFFFAOYSA-N 5-amino-4-(7-methyl-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound CC1=CC=CC2=C1CN(C(CCC(O)=O)C(N)=O)C2=O RXNLJUZQYUZNDX-UHFFFAOYSA-N 0.000 description 1
• MUVQMLOEDIDSDJ-UHFFFAOYSA-N 5-amino-4-(7-nitro-3-oxo-1h-isoindol-2-yl)-5-oxopentanoic acid Chemical compound O=C1N(C(CCC(O)=O)C(=O)N)CC2=C1C=CC=C2[N+]([O-])=O MUVQMLOEDIDSDJ-UHFFFAOYSA-N 0.000 description 1
• CFHKLVNYNGIZFX-UHFFFAOYSA-N 5-amino-5-oxo-2-(3-oxo-1-propan-2-yl-1h-isoindol-2-yl)pentanoic acid Chemical compound C1=CC=C2C(C(C)C)N(C(CCC(N)=O)C(O)=O)C(=O)C2=C1 CFHKLVNYNGIZFX-UHFFFAOYSA-N 0.000 description 1
• SNFMEBYDQGCREP-UHFFFAOYSA-N 5-amino-5-oxo-2-(3-oxo-1-propyl-1h-isoindol-2-yl)pentanoic acid Chemical compound C1=CC=C2C(CCC)N(C(CCC(N)=O)C(O)=O)C(=O)C2=C1 SNFMEBYDQGCREP-UHFFFAOYSA-N 0.000 description 1
• YFNMIAYPKVQJHC-UHFFFAOYSA-N 5-amino-5-oxo-2-(3-oxo-7-propan-2-yl-1h-isoindol-2-yl)pentanoic acid Chemical compound CC(C)C1=CC=CC2=C1CN(C(CCC(N)=O)C(O)=O)C2=O YFNMIAYPKVQJHC-UHFFFAOYSA-N 0.000 description 1
• TYUNAHWJBFTWPM-UHFFFAOYSA-N 5-amino-5-oxo-4-(3-oxo-1-propan-2-yl-1h-isoindol-2-yl)pentanoic acid Chemical compound C1=CC=C2C(C(C)C)N(C(CCC(O)=O)C(N)=O)C(=O)C2=C1 TYUNAHWJBFTWPM-UHFFFAOYSA-N 0.000 description 1
• LZJGXQWYGDOVQX-UHFFFAOYSA-N 5-amino-5-oxo-4-(3-oxo-1-propyl-1h-isoindol-2-yl)pentanoic acid Chemical compound C1=CC=C2C(CCC)N(C(CCC(O)=O)C(N)=O)C(=O)C2=C1 LZJGXQWYGDOVQX-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• ZOXBWJMCXHTKNU-UHFFFAOYSA-N 5-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=C2C(=O)OC(=O)C2=C1 ZOXBWJMCXHTKNU-UHFFFAOYSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 235000006491 Acacia senegal Nutrition 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000012526 B-cell neoplasm Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 206010063094 Cerebral malaria Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 239000004099 Chlortetracycline Substances 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 206010010755 Conjunctivitis viral Diseases 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 208000037487 Endotoxemia Diseases 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 241000713730 Equine infectious anemia virus Species 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 241000713800 Feline immunodeficiency virus Species 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010020164 HIV infection CDC Group III Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
• 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 102100026236 Interleukin-8 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• PMLJIHNCYNOQEQ-REOHCLBHSA-N L-aspartic 1-amide Chemical compound NC(=O)[C@@H](N)CC(O)=O PMLJIHNCYNOQEQ-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• 206010024179 Legionella infections Diseases 0.000 description 1
• 208000004023 Legionellosis Diseases 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 201000000090 Microsporidiosis Diseases 0.000 description 1
• 208000010718 Multiple Organ Failure Diseases 0.000 description 1
• 241000711408 Murine respirovirus Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 206010062207 Mycobacterial infection Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 108091093105 Nuclear DNA Proteins 0.000 description 1
• 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 208000003076 Osteolysis Diseases 0.000 description 1
• 206010031252 Osteomyelitis Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 241000282320 Panthera leo Species 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
• 208000012641 Pigmentation disease Diseases 0.000 description 1
• 102100035194 Placenta growth factor Human genes 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
• 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
• 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010053879 Sepsis syndrome Diseases 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 102100026966 Thrombomodulin Human genes 0.000 description 1
• 108010079274 Thrombomodulin Proteins 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
• 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
• 241000713325 Visna/maedi virus Species 0.000 description 1
• 102100029477 Vitamin K-dependent protein C Human genes 0.000 description 1
• 101710193900 Vitamin K-dependent protein C Proteins 0.000 description 1
• GIUYCYHIANZCFB-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O GIUYCYHIANZCFB-UUOKFMHZSA-N 0.000 description 1
• VRGWBRLULZUWAJ-XFFXIZSCSA-N [(2s)-2-[(1r,3z,5s,8z,12z,15s)-5,17-dihydroxy-4,8,12,15-tetramethyl-16-oxo-18-bicyclo[13.3.0]octadeca-3,8,12,17-tetraenyl]propyl] acetate Chemical compound C1\C=C(C)/CC\C=C(C)/CC[C@H](O)\C(C)=C/C[C@@H]2C([C@@H](COC(C)=O)C)=C(O)C(=O)[C@]21C VRGWBRLULZUWAJ-XFFXIZSCSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 210000005091 airway smooth muscle Anatomy 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000008382 alveolar damage Effects 0.000 description 1
• 210000001132 alveolar macrophage Anatomy 0.000 description 1
• 230000006427 angiogenic response Effects 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 208000002399 aphthous stomatitis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 239000010425 asbestos Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 230000015624 blood vessel development Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 208000019664 bone resorption disease Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical class CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
• 239000000378 calcium silicate Substances 0.000 description 1
• 229910052918 calcium silicate Inorganic materials 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
• LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
• 150000001734 carboxylic acid salts Chemical class 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000004709 cell invasion Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
• 229960004475 chlortetracycline Drugs 0.000 description 1
• CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
• 235000019365 chlortetracycline Nutrition 0.000 description 1
• 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
• 208000019902 chronic diarrheal disease Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000005796 circulatory shock Effects 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000012050 conventional carrier Substances 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 229960002398 demeclocycline Drugs 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• VRHAQNTWKSVEEC-UHFFFAOYSA-N ethyl 1,3-dioxoisoindole-2-carboxylate Chemical class C1=CC=C2C(=O)N(C(=O)OCC)C(=O)C2=C1 VRHAQNTWKSVEEC-UHFFFAOYSA-N 0.000 description 1
• NUJJHSPYMWDZSJ-UHFFFAOYSA-N ethyl 4-nitro-1,3-dioxoisoindole-2-carboxylate Chemical compound C1=CC([N+]([O-])=O)=C2C(=O)N(C(=O)OCC)C(=O)C2=C1 NUJJHSPYMWDZSJ-UHFFFAOYSA-N 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 230000009791 fibrotic reaction Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 229960000936 fumagillin Drugs 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• VRGWBRLULZUWAJ-UHFFFAOYSA-N fusaproliferin Natural products C1C=C(C)CCC=C(C)CCC(O)C(C)=CCC2C(C(COC(C)=O)C)=C(O)C(=O)C21C VRGWBRLULZUWAJ-UHFFFAOYSA-N 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 229940125697 hormonal agent Drugs 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 150000003949 imides Chemical class 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 229940124622 immune-modulator drug Drugs 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000003960 inflammatory cascade Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000011344 liquid material Substances 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 229960004196 lymecycline Drugs 0.000 description 1
• AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000002395 mineralocorticoid Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical class NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 229940127073 nucleoside analogue Drugs 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 230000033667 organ regeneration Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 231100000255 pathogenic effect Toxicity 0.000 description 1
• 230000008529 pathological progression Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 230000019612 pigmentation Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000009290 primary effect Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 229930185346 proliferin Natural products 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000027272 reproductive process Effects 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229910052895 riebeckite Inorganic materials 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000012056 semi-solid material Substances 0.000 description 1
• 235000020046 sherry Nutrition 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000012058 sterile packaged powder Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940040944 tetracyclines Drugs 0.000 description 1
• AODPIQQILQLWGS-GXBDJPPSSA-N tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 AODPIQQILQLWGS-GXBDJPPSSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 210000001585 trabecular meshwork Anatomy 0.000 description 1
• 108091006106 transcriptional activators Proteins 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 208000010380 tumor lysis syndrome Diseases 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1